Dyne Therapeutics Chief Medical Officer Kerr Douglas sold 5,035 shares in two transactions priced from $18.88 to $24.35 per share, leaving him with 162,564 shares. The transaction gives investors a current view of an insider’s remaining ownership and the prices attached to the reported sales.
Key Highlights
- Kerr Douglas held 162,564 Dyne Therapeutics shares after the transactions.
- The sales occurred across two transactions between September 4 and September 8, 2026.
- Both transactions carried SEC transaction code S, classifying them as open-market sales.
Dyne Therapeutics, Inc. (NASDAQ: DYN) Chief Medical Officer Kerr Douglas sold 5,035 shares at prices ranging from $18.88 to $24.35 per share. The two transactions leave Douglas with 162,564 shares of Dyne Therapeutics.
The sales took place between September 4 and September 8, 2026. The reported price range was $18.88 to $24.35 per share. Douglas remains a holder of Dyne Therapeutics stock after the transactions. His reported post-transaction ownership stands at 162,564 shares.
FAQs
Q: How many Dyne Therapeutics shares did Kerr Douglas sell?
A: Kerr Douglas sold 5,035 Dyne Therapeutics shares. The chief medical officer completed the sales across two transactions at prices ranging from $18.88 to $24.35 per share.
Q: What was the price range for the Dyne Therapeutics insider sale?
A: The reported insider sale prices ranged from $18.88 to $24.35 per share. The transactions occurred between September 4 and September 8, 2026.
Q: How many Dyne Therapeutics shares does Kerr Douglas still own?
A: Kerr Douglas still owns 162,564 shares of Dyne Therapeutics after the reported transactions. The sales took place between September 4 and September 8, 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.